Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.

ABSTRACT:

Background

Staphylococcus aureus bacteremia (SAB) is a prevalent life-threatening infection often caused by methicillin-resistant S. aureus (MRSA). Up to 30% of SAB patients fail to clear infection even with gold-standard anti-MRSA antibiotics. This phenomenon is termed antibiotic-persistent MRSA bacteremia (APMB). The mechanisms driving APMB are complex and involve host phenotypes significantly impacting the immune response. Thus, defining early immune signatures and clinical phenotypes that differentiate APMB from antibiotic resolving (AR)MB could aid therapeutic success.

Methods

We assessed 38 circulating cytokines and chemokines using affinity proteomics in 74 matched pairs of vancomycin-treated SAB cases identified as ARMB or APMB after 5 days of blood culture.

Resul

SUBMITTER: Bergersen KV 

PROVIDER: S-EPMC11834594 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature